Results 31 to 40 of about 29,286 (231)

Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity.

, 2023
Click on the Resource Link to access the article (may not be free).Background: Dasatinib has been associated with nephrotoxicity. We sought to examine the incidence of proteinuria on dasatinib and determine potential risk factors that may increase ...
Campbell, Kirk N, Chan, Lili, Musteata, Florin Marcel, Salvatore, Steven P, Muwonge, Alecia N, Kremyanskaya, Marina, Abramson, Matthew H, Azeloglu, Evren U, El Ghaity-Beckley, Sebastian, Berman, Ellin M, Meliambro, Kristin A, Marcellino, Bridget, Gutgarts, Victoria, Jaimes, Edgar A, Chauhan, Kinsuk, Adegbite, Benjamin O, Mascarenhas, John O, Coca, Steven G   +17 more
core   +1 more source

Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia

Journal of Pharmacological Sciences, 2022
Although the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia is known to cause vascular adverse events (VAEs), the frequency of VAEs during dasatinib administration is not high, and the same holds for atherosclerosis ...
Masamitsu Takaba, Takayuki Iwaki, Tomohiro Arakawa, Takaaki Ono, Yuichiro Maekawa, Kazuo Umemura   +5 more
doaj   +1 more source

Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes

Cancer Medicine, 2016
It has been shown that an increase in cytotoxic lymphocyte counts in the peripheral blood occurs rapidly after taking dasatinib, but the underlying mechanism is not yet elucidated. To investigate the influence of dasatinib on signal transduction pathways,
Noriyoshi Iriyama, Yoshihiro Hatta, Masami Takei   +2 more
doaj   +1 more source

Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug

Translational Oncology, 2016
Dasatinib is a common anticancer drug used in the treatment of leukemia. Several side effects have been reported, the most common being myelosuppression, diarrhea, edema, and nausea.
Fidencio Davalos, Benjamin Chaucer, Wahib Zafar, Shamim Salman, Jay Nfonoyim   +4 more
doaj   +1 more source

Dasatinib enhances curcumin-induced cytotoxicity, apoptosis and protective autophagy in human schwannoma cells HEI-193: The role of Akt/mTOR/p70S6K signalling pathway

Acta Pharmaceutica, 2022
The present study was carried out in human schwannoma cells (HEI-193) to determine the combined anti-cancer effect of curcumin and dasatinib. Cells were treated with curcumin only, dasatinib only, or the combination of curcumin and dasatinib for 24 hours.
Pang Pengfei, Zhang Shirong
doaj   +1 more source

Src Family Kinase/Abl Inhibitor Dasatinib Suppresses Proliferation and Enhances Differentiation of Osteoblasts

, 2011
Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate ...
Lee, Y-C; Huang, C-F; Murshed, M; Chu, K; Araujo, J C; Ye, X; deCrombrugghe, B; Yu-Lee, L-Y; Gallick, G E; Lin, S-H, 黃織芬;林淑華   +1 more
core   +1 more source

Efficacy and Safety of Dasatinib in Imatinib-Resistant or -Intolerant Patients with Chronic Myeloid Leukemia in Blast Phase

, 2011
Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally ( 70mg twice daily) to patients ...
唐季祿, Cortes, J; Kim, D-W; Raffoux, E; Martinelli, G; Ritchie, E; Roy, L; Coutre, S; Corm, S; Hamerschlak, N; Tang, J-L; Hochhaus, A; Khoury, H J; Brümmendorf, T H; Michallet, M; Rege-Cambrin, G   +1 more
core   +1 more source

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Experimental Hematology & Oncology, 2012
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients.
Gadó Klára, Matolcsy András, Csomor Judit, Kicsi Dóra, Bödör Csaba, Domján Gyula   +5 more
doaj   +1 more source

Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury

Journal of Inflammation, 2020
Background Neutrophils rapidly respond to and clear infection from tissues, but can also induce tissue damage through excessive degranulation, when acute inflammation proceeds unchecked.
James G. Macfarlane, David A. Dorward, Marie-Hélène Ruchaud-Sparagano, Jonathan Scott, Christopher D. Lucas, Adriano G. Rossi, A. John Simpson   +6 more
doaj   +1 more source

A Skull Bone Marrow‐to‐Brain Axis Links Osteoblastic Activity to Myeloid Cell Trafficking, Cerebral Blood Flow, and Cognition in Alzheimer's Progression

Advanced Science, EarlyView.
This study reveals that Alzheimer's disease–linked APP expression in bone‐forming cells drives skull bone marrow remodeling and alters its vascular connections to the brain. These changes disrupt immune cell trafficking, cerebral blood flow, and cognition. Targeting bone marrow macrophages restores brain function, highlighting a previously unrecognized
Lei Xiong, Dong Sun, Hao‐Han Guo, Daehoon Lee, Zhipeng Liu, Lin Mei, Wen‐Cheng Xiong   +6 more
wiley   +1 more source